<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153878</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1300803</org_study_id>
    <nct_id>NCT03153878</nct_id>
  </id_info>
  <brief_title>The Prospective Cohort Study on the Benefit-risk of Antithrombotic or Anticoagulant Therapy in Patients With Unruptured Intracranial Aneurysms Associated With Ischemic Heart Disease or Ischemic Cerebrovascular Disease</brief_title>
  <official_title>The Prospective Cohort Study on the Benefit-risk of Antithrombotic or Anticoagulant Therapy in Patients With Unruptured Intracranial Aneurysms Associated With Ischemic Heart Disease or Ischemic Cerebrovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liu Zhiyong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a registry study of the natural course of unruptured intracranial aneurysms (UIA). In
      addition, the investigators will analyze the benefit-risk of antithrombotic or anticoagulant
      therapy in patients with unruptured intracranial aneurysms associated with ischemic heart
      disease or ischemic cerebrovascular disease. The investigators aim to use research data to
      create a China national database of UIA
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a registry study of the natural course of unruptured intracranial aneurysms (UIA). In
      addition, the investigators will analyze the benefit-risk of antithrombotic or anticoagulant
      therapy in patients with unruptured intracranial aneurysms associated with ischemic heart
      disease or ischemic cerebrovascular disease. The investigators aim to use research data to
      create a China national database of UIA. This study is supported by a research grant from the
      Ministry of Science and Technology of the People's Republic of China. The investigators will
      collaborate with the other 19 medical centers which locate in the different districts of
      China.

      During the study period, all the patients included in this study will observe and treat in
      the collaborating medical centers. Included patients will be followed-up for at least 1year.
      Research data will represent the real natural course of UIA in China. For this study, the
      investigators consulted and hired professional experts about data collection, data and
      methodology. An intact systematic project steering committee, including Data Monitoring
      Committee, Data Management Committee, Project Academic Committee, Executive Group, Project
      Manager, Project Statistician, and Technical Support Center has been built up. Scientific
      regulations have also been made
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Aneurysm rupture</measure>
    <time_frame>Up to 4 years or time of aneurysm repair surgery</time_frame>
    <description>Aneurysm rupture</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morphological changes of aneurysms</measure>
    <time_frame>Up to 4 years or time of aneurysm repair surgery</time_frame>
    <description>maximum diameter increase â‰¥ 1mm or appearance of a daughter sac</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction</measure>
    <time_frame>Up to 4 years]</time_frame>
    <description>Acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New onset ischemic stroke</measure>
    <time_frame>Up to 4 years]</time_frame>
    <description>New onset ischemic stroke</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <condition>Natural History</condition>
  <condition>Ischemic Heart Disease</condition>
  <condition>Ischemic Cerebrovascular Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with unruptured intracranial aneurysms associated with ischemic heart disease
        or ischemic cerebrovascular disease,who accept antithrombotic or anticoagulant therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of untreated unruptured intracranial aneurysm (by CTA, MRA or DSA);

          2. Patient with premorbid mRS of 3 or less;

          3. Patient older than 14years;

          4. Patient consenting to participate to the study;

          5. Patients with a definite history of ischemic heart disease or ischemic stroke who
             accept antithrombotic or anticoagulant therapy for secondary pevention

        Exclusion Criteria:

        Subarachnoid hemorrhage with unknown causes;

        - Page 4 of 4 [DRAFT] - 2. Patient with other cerebral arteriovenous malformations or
        cerebral arteriovenous fistulas; 3. Patient with malignant tumor; 4. Target aneurysm is
        fusiform, traumatic, mycotic, or dissecting related; 5. Inability to obtain informed
        consent; 6. Patients with a life expectancy less than 1 year; 7. Participating in the other
        clinical studies of intracranial aneurysm; 8. Refusal of follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min He, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhiyong Liu, M.D, Ph.D</last_name>
    <phone>+8613658021726</phone>
    <email>doctor_lzy@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Li, M.D, Ph.D</last_name>
    <phone>+13683482059</phone>
    <email>jimlijin76@126.com</email>
  </overall_contact_backup>
  <reference>
    <citation>International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms--risk of rupture and risks of surgical intervention. N Engl J Med. 1998 Dec 10;339(24):1725-33. Erratum in: N Engl J Med 1999 Mar 4;340(9):744.</citation>
    <PMID>9867550</PMID>
  </reference>
  <reference>
    <citation>Wiebers DO, Whisnant JP, Huston J 3rd, Meissner I, Brown RD Jr, Piepgras DG, Forbes GS, Thielen K, Nichols D, O'Fallon WM, Peacock J, Jaeger L, Kassell NF, Kongable-Beckman GL, Torner JC; International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003 Jul 12;362(9378):103-10.</citation>
    <PMID>12867109</PMID>
  </reference>
  <reference>
    <citation>UCAS Japan Investigators, Morita A, Kirino T, Hashi K, Aoki N, Fukuhara S, Hashimoto N, Nakayama T, Sakai M, Teramoto A, Tominari S, Yoshimoto T. The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med. 2012 Jun 28;366(26):2474-82. doi: 10.1056/NEJMoa1113260.</citation>
    <PMID>22738097</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Liu Zhiyong</investigator_full_name>
    <investigator_title>Research associate</investigator_title>
  </responsible_party>
  <keyword>Unruptured Intracranial Aneurysm</keyword>
  <keyword>Benefit-risk</keyword>
  <keyword>Ischemic heart disease</keyword>
  <keyword>Ischemic cerebrovascular disease</keyword>
  <keyword>Antithrombotic</keyword>
  <keyword>Anticoagulant</keyword>
  <keyword>People's Republic of China</keyword>
  <keyword>Multicenter Studies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>share the original data 5 years after the study completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

